Share this video  

ASCO 2020 | Intracranial activity of selpercatinib in RET fusion positive NSCLC

Vivek Subbiah, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, described the LIBRETTO-001 study (NCT03157128), a phase I/II study of selpercatinib, a RET inhibitor, in patients with RET fusion positive NSCLC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).